251 related articles for article (PubMed ID: 9448878)
1. Hyperprolactinaemia in males: a heterogeneous disorder.
Walsh JP; Pullan PT
Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
3. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Greenman Y; Tordjman K; Stern N
Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
[TBL] [Abstract][Full Text] [Related]
4. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
van 't Verlaat JW; Croughs RJ
Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
[TBL] [Abstract][Full Text] [Related]
6. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy.
Howlett TA; Wass JA; Grossman A; Plowman PN; Charlesworth M; Touzel R; Rees LH; Savage MO; Besser GM
Clin Endocrinol (Oxf); 1989 Feb; 30(2):131-40. PubMed ID: 2612015
[TBL] [Abstract][Full Text] [Related]
7. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
Tyson D; Reggiardo D; Sklar C; David R
Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
[TBL] [Abstract][Full Text] [Related]
8. Screening for macroprolactinaemia and pituitary imaging studies.
Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
[TBL] [Abstract][Full Text] [Related]
9. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
[TBL] [Abstract][Full Text] [Related]
11. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
16. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
18. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
19. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine treatment of males with pituitary tumours, hyperprolactinaemia, and hypogonadism.
Nagulesparen M; Ang V; Jenkins JS
Clin Endocrinol (Oxf); 1978 Jul; 9(1):73-9. PubMed ID: 679504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
